Skip to main content


Fig. 3 | EJNMMI Research

Fig. 3

From: Comprehensive analysis of the influence of G-CSF on the biodistribution of 18F-FDG in lymphoma patients: insights for PET/CT scheduling

Fig. 3

A 47-year-old female patient imaged at baseline (a, b) and after 4 cycles of R-ACVP (c, d). Interim PET/CT was performed 17 days and 12 days following the last injection of chemotherapy and G-CSF, respectively. The injected G-CSF was lenogastrim, at a dosage of 34MUI daily for a 5-day period. Thanks to a time-lapse between the last chemotherapy injection and interim PET/CT, no significant increased bone marrow or splenic uptake are observed

Back to article page